The US FDA `Black Box' Warning for Topical Calcineurin Inhibitors: An Ongoing Controversy

Author： Ring Johannes  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.3, 2008-01, pp. : 185-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The recent US FDA decision to issue a black box warning for ultrasound contrast agents (UCAs) may do more harm than good

By  

Inpharma, Vol. 1, Iss. 1633, 2008-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Black-box warning messages differ between FDA, lay media

By  

Reactions Weekly, Vol. 1, Iss. 1282, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Rosiglitazone: FDA must provide more than black box warning

By  

Reactions Weekly, Vol. 1, Iss. 1314, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Black box warning added to US Dryvax label

By  

Reactions Weekly, Vol. 1, Iss. 1029, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

New black box warning for nefazodone in the US

By  

Inpharma, Vol. 1, Iss. 1321, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite